DDInter605 DDInter1729
Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) causes {v} (Side Effect) Vascular purpura
Vascular purpura {u} (Side Effect) is caused by {v} (Compound) Sulindac
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvoxamine
Fluvoxamine {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Sulindac
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Tirofiban
Tirofiban {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Sulindac
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Meclofenamic acid
Meclofenamic acid {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Sulindac
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Ketorolac
Ketorolac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Sulindac
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Treprostinil
Treprostinil {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PPARD
PPARD {u} (Gene) is bound by {v} (Compound) Sulindac
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Oxaprozin
Oxaprozin {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Sulindac
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) causes Vascular purpura (Side Effect) and Vascular purpura (Side Effect) is caused by Sulindac (Compound)
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Sulindac (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Sulindac (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Meclofenamic acid and Meclofenamic acid (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Sulindac (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Sulindac (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil (Compound) binds PPARD (Gene) and Treprostinil (Compound) upregulates PPARD (Gene) and PPARD (Gene) is bound by Sulindac (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Oxaprozin and Oxaprozin (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Sulindac (Compound)